Posted on | Posted on John Murphy | Leave a Comment on Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants

Lorenza Bellusci, Hana Golding, and Surender Khurana Journal of Clinical Investigation Published 2023 - More infoView PDF  Convalescent plasma (CP) and hyperimmune intravenous immunoglobulins (IVIGs) are routinely used to treat patients with COVID-19.…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps

Bruna M. Silva,1,2 Giovanni F. Gomes,1 Flavio P. Veras,1 Seppe Cambier,3 Gabriel V.L. Silva,1,2 Andreza U. Quadros,1 Diego B. Caetité,1,2 Daniele C. Nascimento,1,2 Camilla M. Silva,1,2 Juliana C. Silva,1 Samara Damasceno,1 Ayda H. Schneider,1 Fabio Beretta,3 Sabrina S. Batah,4 Icaro M.S. Castro,5 Isadora M. Paiva,1 Tamara…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Treatments of COVID-19-Associated Taste and Saliva Secretory Disorders

Hironori Tsuchiya, Christos Rahiotis, Academic Editor and Nikolaos Gkantidis, Academic EditorDent J (Basel). 2023 Jun; 11(6): 140. Published online 2023 May 25. doi: 10.3390/dj11060140, PMCID: PMC10297082 PMID: 37366663 Abstract Since the worldwide spread of severe acute respiratory syndrome…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Insurance Industry Execs ‘Alarmed’ by Surge in Deaths Among Young People — But Stop Short of Blaming COVID Shots

Insurance Industry Execs ‘Alarmed’ by Surge in Deaths Among Young People — But Stop Short of Blaming COVID Shots

According to InsuranceNewsNet, insurers are especially concerned by data from the Centers for Disease Control and Prevention that show “mortality rates alarmingly rising for different categories,” including younger adult mortality…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes

Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield, Hassan Hartman, Alessandra Løchen, Thomas P. Peacock & Christopher Ruis Nature (2023) Cite this article Abstract Molnupiravir, an antiviral medication widely used against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), acts by inducing…[...]

Read More
Posted on | Posted on John Murphy | Leave a Comment on Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19A Randomized Clinical Trial

Susanna Naggie, MD, MHS1,2; David R. Boulware, MD, MPH3; Christopher J. Lindsell, PhD4; et alThomas G. Stewart, PhD5; Alex J. Slandzicki, MD6; Stephen, C. Lim,  MD Jonathan Cohen, MD8;  David Kavtaradze, MD9,  Arch Amon, MD10, et. al for the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators. JAMA. 2023;329(11):888-897. doi:10.1001/jama.2023.1650 Question  Does ivermectin,…[...]

Read More